XML 15 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Shareholder’s Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2022 $ 146,211 $ 232,368,121 $ (129,688,467) $ 102,825,865 $ 600,380 $ 103,426,245
Balance (in Shares) at Sep. 30, 2022   146,211,130          
Stock-based compensation expense 1,201,081 1,201,081 1,201,081
Net loss (3,593,645) (3,593,645) (3,593,645)
Balance at Dec. 31, 2022 $ 146,211 233,569,202 (133,282,112) 100,433,301 600,380 101,033,681
Balance (in Shares) at Dec. 31, 2022   146,211,130          
Balance at Sep. 30, 2023 $ 158,858 252,903,629 (162,231,379) 90,831,108 600,380 91,431,488
Balance (in Shares) at Sep. 30, 2023   158,857,798          
Issuance of common stock for services $ 109 76,037 76,146 76,146
Issuance of common stock for services (in Shares)   108,778          
Stock-based compensation expense 3,058,185 3,058,185 3,058,185
Net loss (9,231,185) (9,231,185) (9,231,185)
Balance at Dec. 31, 2023 $ 158,967 $ 256,037,851 $ (171,462,564) $ 84,734,254 $ 600,380 $ 85,334,634
Balance (in Shares) at Dec. 31, 2023   158,966,576